ID

DB08950||

名称

Indoramin

描述

Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

cas号

26844-12-2

唯一标识码

0Z802HMY7H

状态

solid

组

approved,withdrawn,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
direct-parent:Tryptamines and derivatives
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Indoles and derivatives
subclass:Tryptamines and derivatives
alternative-parent:3-alkylindoles
alternative-parent:Amino acids and derivatives
alternative-parent:Aralkylamines
alternative-parent:Azacyclic compounds
alternative-parent:Benzamides
alternative-parent:Benzoyl derivatives
alternative-parent:Heteroaromatic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organooxygen compounds
alternative-parent:Organopnictogen compounds
alternative-parent:Piperidines
alternative-parent:Secondary carboxylic acid amides
alternative-parent:Substituted pyrroles
alternative-parent:Trialkylamines
substituent:3-alkylindole
substituent:Amine
substituent:Amino acid or derivatives
substituent:Aralkylamine
substituent:Aromatic heteropolycyclic compound
substituent:Azacycle
substituent:Benzamide
substituent:Benzenoid
substituent:Benzoic acid or derivatives
substituent:Benzoyl
substituent:Carboxamide group
substituent:Carboxylic acid derivative
substituent:Heteroaromatic compound
substituent:Hydrocarbon derivative
substituent:Indole
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Piperidine
substituent:Pyrrole
substituent:Secondary carboxylic acid amide
substituent:Substituted pyrrole
substituent:Tertiary aliphatic amine
substituent:Tertiary amine
substituent:Tryptamine

消除途径

种类

Acids, Carbocyclic
D000146
Adrenergic Agents
D018663
Adrenergic alpha-1 Receptor Antagonists
D058668
Adrenergic alpha-Antagonists
D000317
Adrenergic Antagonists
D018674
Agents that produce hypertension

Amides
D000577
Antiadrenergic Agents, Peripherally Acting

Antihypertensive Agents
D000959
Benzamides and benzamide derivatives
D001549
Benzene Derivatives
D001555
Benzoates
D001565
Cardiovascular Agents
D002317
Heterocyclic Compounds, Fused-Ring
D000072471
Hypotensive Agents

Indoles
D007211
Neurotransmitter Agents
D018377
Peripheral alpha-1 blockers

Piperidines
D010880

盐类

DBSALT001077Indoramin hydrochlorideDQ0Z3K8W9238821-52-2AFJSFHAKSSWOKG-UHFFFAOYSA-N383.92383.1764402

蛋白质结合

清除

同义词

language:english; code:inn/ban/usan; name;Indoramin
language:english; code:dcit; name;Indoramina
language:english; code:dcf; name;Indoramine
language:latin; code:inn; name;Indoraminum

国际品牌

BaratolAmdipharmDoraleseGlaxoSmithKline / ChemidexVidoraLeurquinWydoraRiemser

配送量

产品

混合物

包装者

生产者

价格

受影响的生物体

剂量

form:Tablet
route:
strength:25 MG
form:Tablet
route:
strength:50 MG

atc代码

Alpha-adrenoreceptor antagonists
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
ANTIHYPERTENSIVES
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB08950.pdf?1401218842

专利

食物相互作用

药物相互作用

DB00476
The risk or severity of orthostatic hypotension and syncope can be increased when Indoramin is combined with Duloxetine.
DB01235
The risk or severity of hypotension and orthostatic hypotension can be increased when Indoramin is combined with Levodopa.
DB00734
Indoramin may increase the hypotensive activities of Risperidone.
DB00346
Alfuzosin may increase the hypotensive activities of Indoramin.
DB01143
Indoramin may increase the hypotensive activities of Amifostine.
DB01119
Diazoxide may increase the hypotensive activities of Indoramin.
DB00422
Methylphenidate may decrease the antihypertensive activities of Indoramin.
DB06701
Dexmethylphenidate may decrease the antihypertensive activities of Indoramin.
DB08935
Indoramin may increase the hypotensive activities of Obinutuzumab.
DB00806
Pentoxifylline may increase the hypotensive activities of Indoramin.
DB00073
Indoramin may increase the hypotensive activities of Rituximab.
DB01392
Yohimbine may decrease the antihypertensive activities of Indoramin.
DB02032
Epicaptopril may decrease the antihypertensive activities of Indoramin.
DB12371
Siponimod may decrease the antihypertensive activities of Indoramin.
DB00177
Valsartan may decrease the antihypertensive activities of Indoramin.
DB00178
Ramipril may decrease the antihypertensive activities of Indoramin.
DB00206
Reserpine may decrease the antihypertensive activities of Indoramin.
DB00214
Torasemide may decrease the antihypertensive activities of Indoramin.
DB00275
Olmesartan may decrease the antihypertensive activities of Indoramin.
DB00310
Chlorthalidone may decrease the antihypertensive activities of Indoramin.
DB00325
Nitroprusside may decrease the antihypertensive activities of Indoramin.
DB00350
Minoxidil may decrease the antihypertensive activities of Indoramin.
DB00492
Fosinopril may decrease the antihypertensive activities of Indoramin.
DB00519
Trandolapril may decrease the antihypertensive activities of Indoramin.
DB00524
Metolazone may decrease the antihypertensive activities of Indoramin.
DB00542
Benazepril may decrease the antihypertensive activities of Indoramin.
DB00584
Enalapril may decrease the antihypertensive activities of Indoramin.
DB00657
Mecamylamine may decrease the antihypertensive activities of Indoramin.
DB00678
Losartan may decrease the antihypertensive activities of Indoramin.
DB00691
Moexipril may decrease the antihypertensive activities of Indoramin.
DB00695
Furosemide may decrease the antihypertensive activities of Indoramin.
DB00700
Eplerenone may decrease the antihypertensive activities of Indoramin.
DB00708
Sufentanil may decrease the antihypertensive activities of Indoramin.
DB00722
Lisinopril may decrease the antihypertensive activities of Indoramin.
DB00727
Nitroglycerin may decrease the antihypertensive activities of Indoramin.
DB00753
Isoflurane may decrease the antihypertensive activities of Indoramin.
DB00790
Perindopril may decrease the antihypertensive activities of Indoramin.
DB00796
Candesartan cilexetil may decrease the antihypertensive activities of Indoramin.
DB00800
Fenoldopam may decrease the antihypertensive activities of Indoramin.
DB00818
Propofol may decrease the antihypertensive activities of Indoramin.
DB00876
Eprosartan may decrease the antihypertensive activities of Indoramin.
DB00881
Quinapril may decrease the antihypertensive activities of Indoramin.
DB00899
Remifentanil may decrease the antihypertensive activities of Indoramin.
DB00966
Telmisartan may decrease the antihypertensive activities of Indoramin.
DB01029
Irbesartan may decrease the antihypertensive activities of Indoramin.
DB01158
Bretylium may decrease the antihypertensive activities of Indoramin.
DB01159
Halothane may decrease the antihypertensive activities of Indoramin.
DB01189
Desflurane may decrease the antihypertensive activities of Indoramin.
DB01197
Captopril may decrease the antihypertensive activities of Indoramin.
DB01236
Sevoflurane may decrease the antihypertensive activities of Indoramin.
DB01242
Clomipramine may decrease the antihypertensive activities of Indoramin.
DB01275
Hydralazine may decrease the antihypertensive activities of Indoramin.
DB01340
Cilazapril may decrease the antihypertensive activities of Indoramin.
DB05271
Rotigotine may decrease the antihypertensive activities of Indoramin.
DB08931
Riociguat may decrease the antihypertensive activities of Indoramin.
DB00212
Indoramin may decrease the antihypertensive activities of Remikiren.
DB00226
Indoramin may decrease the antihypertensive activities of Guanadrel.
DB00559
Indoramin may decrease the antihypertensive activities of Bosentan.
DB00616
Indoramin may decrease the antihypertensive activities of Candoxatril.
DB00765
Indoramin may decrease the antihypertensive activities of Metyrosine.
DB00785
Indoramin may decrease the antihypertensive activities of Cryptenamine.
DB00886
Indoramin may decrease the antihypertensive activities of Omapatrilat.
DB01089
Indoramin may decrease the antihypertensive activities of Deserpidine.
DB01090
Indoramin may decrease the antihypertensive activities of Pentolinium.
DB01116
Indoramin may decrease the antihypertensive activities of Trimethaphan.
DB01170
Indoramin may decrease the antihypertensive activities of Guanethidine.
DB01180
Indoramin may decrease the antihypertensive activities of Rescinnamine.
DB01347
Indoramin may decrease the antihypertensive activities of Saprisartan.
DB01348
Indoramin may decrease the antihypertensive activities of Spirapril.
DB04831
Indoramin may decrease the antihypertensive activities of Tienilic acid.
DB04840
Indoramin may decrease the antihypertensive activities of Debrisoquine.
DB06268
Indoramin may decrease the antihypertensive activities of Sitaxentan.
DB06403
Indoramin may decrease the antihypertensive activities of Ambrisentan.
DB06445
Indoramin may decrease the antihypertensive activities of Diethylnorspermine.
DB06762
Indoramin may decrease the antihypertensive activities of Pinacidil.
DB07767
Indoramin may decrease the antihypertensive activities of Ferulic acid.
DB08836
Indoramin may decrease the antihypertensive activities of Temocapril.
DB08932
Indoramin may decrease the antihypertensive activities of Macitentan.
DB08960
Indoramin may decrease the antihypertensive activities of Hexamethonium.
DB09026
Indoramin may decrease the antihypertensive activities of Aliskiren.
DB09363
Indoramin may decrease the antihypertensive activities of Rauwolfia serpentina root.
DB09477
Indoramin may decrease the antihypertensive activities of Enalaprilat.
DB11362
Indoramin may decrease the antihypertensive activities of Selexipag.
DB11720
Indoramin may decrease the antihypertensive activities of Angiotensin 1-7.
DB11783
Indoramin may decrease the antihypertensive activities of Imidapril.
DB12054
Indoramin may decrease the antihypertensive activities of BQ-123.
DB12465
Indoramin may decrease the antihypertensive activities of Ketanserin.
DB12766
Indoramin may decrease the antihypertensive activities of Cicletanine.
DB12945
Indoramin may decrease the antihypertensive activities of Dihydralazine.
DB13166
Indoramin may decrease the antihypertensive activities of Zofenopril.
DB13211
Indoramin may decrease the antihypertensive activities of Guanoxan.
DB13312
Indoramin may decrease the antihypertensive activities of Delapril.
DB13374
Indoramin may decrease the antihypertensive activities of Vincamine.
DB13400
Indoramin may decrease the antihypertensive activities of Linsidomine.
DB13410
Indoramin may decrease the antihypertensive activities of Guanoxabenz.
DB13429
Indoramin may decrease the antihypertensive activities of Tolonidine.
DB13435
Indoramin may decrease the antihypertensive activities of Endralazine.
DB13452
Indoramin may decrease the antihypertensive activities of Cadralazine.
DB13575
Indoramin may decrease the antihypertensive activities of Bietaserpine.
DB13604
Indoramin may decrease the antihypertensive activities of Guanazodine.
DB13631
Indoramin may decrease the antihypertensive activities of Methoserpidine.
DB13779
Indoramin may decrease the antihypertensive activities of Guanoclor.
DB13801
Indoramin may decrease the antihypertensive activities of Muzolimine.
DB13803
Indoramin may decrease the antihypertensive activities of Xipamide.
DB13919
Indoramin may decrease the antihypertensive activities of Candesartan.
DB14094
Indoramin may decrease the antihypertensive activities of Tocopherylquinone.
DB14125
Indoramin may decrease the antihypertensive activities of Benazeprilat.
DB14207
Indoramin may decrease the antihypertensive activities of Fosinoprilat.
DB14208
Indoramin may decrease the antihypertensive activities of Ramiprilat.
DB14213
Indoramin may decrease the antihypertensive activities of Perindoprilat.
DB14217
Indoramin may decrease the antihypertensive activities of Quinaprilat.
DB00945
Acetylsalicylic acid may decrease the antihypertensive activities of Indoramin.
DB15685
Selpercatinib may decrease the antihypertensive activities of Indoramin.
DB15965
Naxitamab may decrease the antihypertensive activities of Indoramin.
DB09237
Indoramin may decrease the antihypertensive activities of Levamlodipine.
DB00035
The risk or severity of hypertension can be increased when Desmopressin is combined with Indoramin.
DB00091
The risk or severity of hypertension can be increased when Cyclosporine is combined with Indoramin.
DB00216
The risk or severity of hypertension can be increased when Eletriptan is combined with Indoramin.
DB00247
The risk or severity of hypertension can be increased when Methysergide is combined with Indoramin.
DB00248
The risk or severity of hypertension can be increased when Cabergoline is combined with Indoramin.
DB00289
The risk or severity of hypertension can be increased when Atomoxetine is combined with Indoramin.
DB00315
The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indoramin.
DB00344
The risk or severity of hypertension can be increased when Protriptyline is combined with Indoramin.
DB00353
The risk or severity of hypertension can be increased when Methylergometrine is combined with Indoramin.
DB00370
The risk or severity of hypertension can be increased when Mirtazapine is combined with Indoramin.
DB00490
The risk or severity of hypertension can be increased when Buspirone is combined with Indoramin.
DB00561
The risk or severity of hypertension can be increased when Doxapram is combined with Indoramin.
DB00572
The risk or severity of hypertension can be increased when Atropine is combined with Indoramin.
DB00589
The risk or severity of hypertension can be increased when Lisuride is combined with Indoramin.
DB00669
The risk or severity of hypertension can be increased when Sumatriptan is combined with Indoramin.
DB00802
The risk or severity of hypertension can be increased when Alfentanil is combined with Indoramin.
DB00813
The risk or severity of hypertension can be increased when Fentanyl is combined with Indoramin.
DB00830
The risk or severity of hypertension can be increased when Phenmetrazine is combined with Indoramin.
DB00918
The risk or severity of hypertension can be increased when Almotriptan is combined with Indoramin.
DB00952
The risk or severity of hypertension can be increased when Naratriptan is combined with Indoramin.
DB00953
The risk or severity of hypertension can be increased when Rizatriptan is combined with Indoramin.
DB00988
The risk or severity of hypertension can be increased when Dopamine is combined with Indoramin.
DB00998
The risk or severity of hypertension can be increased when Frovatriptan is combined with Indoramin.
DB01028
The risk or severity of hypertension can be increased when Methoxyflurane is combined with Indoramin.
DB01049
The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Indoramin.
DB01126
The risk or severity of hypertension can be increased when Dutasteride is combined with Indoramin.
DB01151
The risk or severity of hypertension can be increased when Desipramine is combined with Indoramin.
DB01216
The risk or severity of hypertension can be increased when Finasteride is combined with Indoramin.
DB01591
The risk or severity of hypertension can be increased when Solifenacin is combined with Indoramin.
DB04581
The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Indoramin.
DB04829
The risk or severity of hypertension can be increased when Lysergic acid diethylamide is combined with Indoramin.
DB04836
The risk or severity of hypertension can be increased when Amineptine is combined with Indoramin.
DB04908
The risk or severity of hypertension can be increased when Flibanserin is combined with Indoramin.
DB05562
The risk or severity of hypertension can be increased when Naluzotan is combined with Indoramin.
DB06016
The risk or severity of hypertension can be increased when Cariprazine is combined with Indoramin.
DB06148
The risk or severity of hypertension can be increased when Mianserin is combined with Indoramin.
DB06678
The risk or severity of hypertension can be increased when Esmirtazapine is combined with Indoramin.
DB06684
The risk or severity of hypertension can be increased when Vilazodone is combined with Indoramin.
DB06690
The risk or severity of hypertension can be increased when Nitrous oxide is combined with Indoramin.
DB06763
The risk or severity of hypertension can be increased when Saralasin is combined with Indoramin.
DB08810
The risk or severity of hypertension can be increased when Cinitapride is combined with Indoramin.
DB08841
The risk or severity of hypertension can be increased when Tyramine is combined with Indoramin.
DB08954
The risk or severity of hypertension can be increased when Indoramin is combined with Ifenprodil.
DB08996
The risk or severity of hypertension can be increased when Indoramin is combined with Dimetacrine.
DB09016
The risk or severity of hypertension can be increased when Indoramin is combined with Butriptyline.
DB09061
The risk or severity of hypertension can be increased when Indoramin is combined with Cannabidiol.
DB09068
The risk or severity of hypertension can be increased when Indoramin is combined with Vortioxetine.
DB09167
The risk or severity of hypertension can be increased when Indoramin is combined with Dosulepin.
DB09205
The risk or severity of hypertension can be increased when Indoramin is combined with Moxisylyte.
DB09289
The risk or severity of hypertension can be increased when Indoramin is combined with Tianeptine.
DB09307
The risk or severity of hypertension can be increased when Indoramin is combined with Oxaprotiline.
DB11273
The risk or severity of hypertension can be increased when Indoramin is combined with Dihydroergocornine.
DB11481
The risk or severity of hypertension can be increased when Indoramin is combined with Atipamezole.
DB11755
The risk or severity of hypertension can be increased when Indoramin is combined with Tetrahydrocannabivarin.
DB12361
The risk or severity of hypertension can be increased when Indoramin is combined with Piclozotan.
DB12551
The risk or severity of hypertension can be increased when Indoramin is combined with Idazoxan.
DB12930
The risk or severity of hypertension can be increased when Indoramin is combined with Opipramol.
DB13064
The risk or severity of hypertension can be increased when Indoramin is combined with Tramazoline.
DB13114
The risk or severity of hypertension can be increased when Indoramin is combined with Amitriptylinoxide.
DB13225
The risk or severity of hypertension can be increased when Indoramin is combined with Dibenzepin.
DB13246
The risk or severity of hypertension can be increased when Indoramin is combined with Quinupramine.
DB13323
The risk or severity of hypertension can be increased when Indoramin is combined with Trichloroethylene.
DB13341
The risk or severity of hypertension can be increased when Indoramin is combined with Fenozolone.
DB13345
The risk or severity of hypertension can be increased when Indoramin is combined with Dihydroergocristine.
DB13384
The risk or severity of hypertension can be increased when Indoramin is combined with Melitracen.
DB13385
The risk or severity of hypertension can be increased when Indoramin is combined with Dihydroergocryptine.
DB13399
The risk or severity of hypertension can be increased when Indoramin is combined with Terguride.
DB13411
The risk or severity of hypertension can be increased when Indoramin is combined with Lofepramine.
DB13453
The risk or severity of hypertension can be increased when Indoramin is combined with Xenon.
DB13496
The risk or severity of hypertension can be increased when Indoramin is combined with Iprindole.
DB13510
The risk or severity of hypertension can be increased when Indoramin is combined with Buflomedil.
DB13520
The risk or severity of hypertension can be increased when Indoramin is combined with Metergoline.
DB13598
The risk or severity of hypertension can be increased when Indoramin is combined with Diethyl ether.
DB13782
The risk or severity of hypertension can be increased when Indoramin is combined with Imipramine oxide.
DB13852
The risk or severity of hypertension can be increased when Indoramin is combined with Mefenorex.
DB14010
The risk or severity of hypertension can be increased when Indoramin is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14231
The risk or severity of hypertension can be increased when Indoramin is combined with Quinoline Yellow WS.
DB04884
Dapoxetine may increase the orthostatic hypotensive activities of Indoramin.
DB08815
Indoramin may increase the hypotensive activities of Lurasidone.
DB00391
The risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.
DB09220
Nicorandil may increase the hypotensive activities of Indoramin.
DB09282
Molsidomine may increase the hypotensive activities of Indoramin.
DB00287
Travoprost may increase the hypotensive activities of Indoramin.
DB00521
Carteolol may increase the hypotensive activities of Indoramin.
DB00869
Dorzolamide may increase the hypotensive activities of Indoramin.
DB00905
Bimatoprost may increase the hypotensive activities of Indoramin.
DB01214
Metipranolol may increase the hypotensive activities of Indoramin.
DB06826
Unoprostone may increase the hypotensive activities of Indoramin.
DB00484
Brimonidine may increase the antihypertensive activities of Indoramin.
DB00217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indoramin.
DB00221
The therapeutic efficacy of Isoetharine can be decreased when used in combination with Indoramin.
DB00292
The therapeutic efficacy of Etomidate can be decreased when used in combination with Indoramin.
DB00397
The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Indoramin.
DB00629
The therapeutic efficacy of Guanabenz can be decreased when used in combination with Indoramin.
DB00633
The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Indoramin.
DB00697
The therapeutic efficacy of Tizanidine can be decreased when used in combination with Indoramin.
DB00816
The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Indoramin.
DB00867
The therapeutic efficacy of Ritodrine can be decreased when used in combination with Indoramin.
DB00871
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Indoramin.
DB00901
The therapeutic efficacy of Bitolterol can be decreased when used in combination with Indoramin.
DB00938
The therapeutic efficacy of Salmeterol can be decreased when used in combination with Indoramin.
DB00968
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Indoramin.
DB00983
The therapeutic efficacy of Formoterol can be decreased when used in combination with Indoramin.
DB01001
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Indoramin.
DB01018
The therapeutic efficacy of Guanfacine can be decreased when used in combination with Indoramin.
DB01064
The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Indoramin.
DB01102
The therapeutic efficacy of Arbutamine can be decreased when used in combination with Indoramin.
DB01274
The therapeutic efficacy of Arformoterol can be decreased when used in combination with Indoramin.
DB01288
The therapeutic efficacy of Fenoterol can be decreased when used in combination with Indoramin.
DB01291
The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Indoramin.
DB01363
The therapeutic efficacy of Ephedra sinica root can be decreased when used in combination with Indoramin.
DB01364
The therapeutic efficacy of Ephedrine can be decreased when used in combination with Indoramin.
DB01366
The therapeutic efficacy of Procaterol can be decreased when used in combination with Indoramin.
DB01407
The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Indoramin.
DB01408
The therapeutic efficacy of Bambuterol can be decreased when used in combination with Indoramin.
DB01537
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Indoramin.
DB04948
The therapeutic efficacy of Lofexidine can be decreased when used in combination with Indoramin.
DB05039
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Indoramin.
DB05395
The therapeutic efficacy of Amibegron can be decreased when used in combination with Indoramin.
DB06190
The therapeutic efficacy of Solabegron can be decreased when used in combination with Indoramin.
DB06694
The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Indoramin.
DB06711
The therapeutic efficacy of Naphazoline can be decreased when used in combination with Indoramin.
DB06814
The therapeutic efficacy of Protokylol can be decreased when used in combination with Indoramin.
DB08893
The therapeutic efficacy of Mirabegron can be decreased when used in combination with Indoramin.
DB08925
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Indoramin.
DB08941
The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Indoramin.
DB08957
The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Indoramin.
DB08985
The therapeutic efficacy of Etilefrine can be decreased when used in combination with Indoramin.
DB09080
The therapeutic efficacy of Olodaterol can be decreased when used in combination with Indoramin.
DB09082
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Indoramin.
DB09203
The therapeutic efficacy of Synephrine can be decreased when used in combination with Indoramin.
DB09242
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Indoramin.
DB09273
The therapeutic efficacy of Doxofylline can be decreased when used in combination with Indoramin.
DB11278
The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Indoramin.
DB11373
The therapeutic efficacy of Amitraz can be decreased when used in combination with Indoramin.
DB11428
The therapeutic efficacy of Medetomidine can be decreased when used in combination with Indoramin.
DB11477
The therapeutic efficacy of Xylazine can be decreased when used in combination with Indoramin.
DB11541
The therapeutic efficacy of Ractopamine can be decreased when used in combination with Indoramin.
DB11543
The therapeutic efficacy of Romifidine can be decreased when used in combination with Indoramin.
DB11556
The therapeutic efficacy of Detomidine can be decreased when used in combination with Indoramin.
DB11587
The therapeutic efficacy of Etafedrine can be decreased when used in combination with Indoramin.
DB11738
The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Indoramin.
DB11871
The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Indoramin.
DB12100
The therapeutic efficacy of Abediterol can be decreased when used in combination with Indoramin.
DB12248
The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Indoramin.
DB12313
The therapeutic efficacy of Dopexamine can be decreased when used in combination with Indoramin.
DB12526
The therapeutic efficacy of Batefenterol can be decreased when used in combination with Indoramin.
DB12779
The therapeutic efficacy of Higenamine can be decreased when used in combination with Indoramin.
DB12846
The therapeutic efficacy of Reproterol can be decreased when used in combination with Indoramin.
DB13139
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Indoramin.
DB13251
The therapeutic efficacy of Octopamine can be decreased when used in combination with Indoramin.
DB13378
The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Indoramin.
DB13398
The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Indoramin.
DB13559
The therapeutic efficacy of Rimiterol can be decreased when used in combination with Indoramin.
DB13692
The therapeutic efficacy of Tretoquinol can be decreased when used in combination with Indoramin.
DB13777
The therapeutic efficacy of Prenalterol can be decreased when used in combination with Indoramin.
DB13781
The therapeutic efficacy of Xamoterol can be decreased when used in combination with Indoramin.
DB14752
The therapeutic efficacy of Racephedrine can be decreased when used in combination with Indoramin.
DB14547
The therapeutic efficacy of Chloride ion can be decreased when used in combination with Indoramin.
DB00187
Esmolol may increase the orthostatic hypotensive activities of Indoramin.
DB00195
Betaxolol may increase the orthostatic hypotensive activities of Indoramin.
DB00264
Metoprolol may increase the orthostatic hypotensive activities of Indoramin.
DB00335
Atenolol may increase the orthostatic hypotensive activities of Indoramin.
DB00373
Timolol may increase the orthostatic hypotensive activities of Indoramin.
DB00489
Sotalol may increase the orthostatic hypotensive activities of Indoramin.
DB00571
Propranolol may increase the orthostatic hypotensive activities of Indoramin.
DB00612
Bisoprolol may increase the orthostatic hypotensive activities of Indoramin.
DB00866
Alprenolol may increase the orthostatic hypotensive activities of Indoramin.
DB00960
Pindolol may increase the orthostatic hypotensive activities of Indoramin.
DB01182
Propafenone may increase the orthostatic hypotensive activities of Indoramin.
DB01193
Acebutolol may increase the orthostatic hypotensive activities of Indoramin.
DB01203
Nadolol may increase the orthostatic hypotensive activities of Indoramin.
DB01297
Practolol may increase the orthostatic hypotensive activities of Indoramin.
DB01359
Penbutolol may increase the orthostatic hypotensive activities of Indoramin.
DB01580
Oxprenolol may increase the orthostatic hypotensive activities of Indoramin.
DB03322
Dexpropranolol may increase the orthostatic hypotensive activities of Indoramin.
DB04846
Celiprolol may increase the orthostatic hypotensive activities of Indoramin.
DB04861
Nebivolol may increase the orthostatic hypotensive activities of Indoramin.
DB06726
Bufuralol may increase the orthostatic hypotensive activities of Indoramin.
DB08807
Bopindolol may increase the orthostatic hypotensive activities of Indoramin.
DB08808
Bupranolol may increase the orthostatic hypotensive activities of Indoramin.
DB08952
Indenolol may increase the orthostatic hypotensive activities of Indoramin.
DB09204
Arotinolol may increase the orthostatic hypotensive activities of Indoramin.
DB09351
Levobetaxolol may increase the orthostatic hypotensive activities of Indoramin.
DB11770
Talinolol may increase the orthostatic hypotensive activities of Indoramin.
DB11785
Anisodamine may increase the orthostatic hypotensive activities of Indoramin.
DB13443
Esatenolol may increase the orthostatic hypotensive activities of Indoramin.
DB13508
Cloranolol may increase the orthostatic hypotensive activities of Indoramin.
DB13530
Mepindolol may increase the orthostatic hypotensive activities of Indoramin.
DB13757
Epanolol may increase the orthostatic hypotensive activities of Indoramin.
DB13775
Tertatolol may increase the orthostatic hypotensive activities of Indoramin.
DB12212
Indoramin may increase the orthostatic hypotensive activities of Landiolol.
DB00374
Treprostinil may increase the hypotensive activities of Indoramin.
DB01088
Iloprost may increase the hypotensive activities of Indoramin.
DB01240
Epoprostenol may increase the hypotensive activities of Indoramin.
DB00468
Quinine may increase the hypotensive activities of Indoramin.
DB14337
Salvia miltiorrhiza root may increase the hypotensive activities of Indoramin.
DB00601
Linezolid may increase the hypotensive activities of Indoramin.
DB00614
Furazolidone may increase the hypotensive activities of Indoramin.
DB00721
Procaine may increase the hypotensive activities of Indoramin.
DB00752
Tranylcypromine may increase the hypotensive activities of Indoramin.
DB00780
Phenelzine may increase the hypotensive activities of Indoramin.
DB00805
Minaprine may increase the hypotensive activities of Indoramin.
DB01037
Selegiline may increase the hypotensive activities of Indoramin.
DB01168
Procarbazine may increase the hypotensive activities of Indoramin.
DB01171
Moclobemide may increase the hypotensive activities of Indoramin.
DB01247
Isocarboxazid may increase the hypotensive activities of Indoramin.
DB01367
Rasagiline may increase the hypotensive activities of Indoramin.
DB01626
Pargyline may increase the hypotensive activities of Indoramin.
DB04017
Clorgiline may increase the hypotensive activities of Indoramin.
DB04818
Iproniazid may increase the hypotensive activities of Indoramin.
DB04820
Nialamide may increase the hypotensive activities of Indoramin.
DB06654
Safinamide may increase the hypotensive activities of Indoramin.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indoramin.
DB09241
Methylene blue may increase the hypotensive activities of Indoramin.
DB09243
Hydracarbazine may increase the hypotensive activities of Indoramin.
DB09244
Pirlindole may increase the hypotensive activities of Indoramin.
DB09245
Toloxatone may increase the hypotensive activities of Indoramin.
DB09246
Benmoxin may increase the hypotensive activities of Indoramin.
DB09248
Mebanazine may increase the hypotensive activities of Indoramin.
DB09249
Octamoxin may increase the hypotensive activities of Indoramin.
DB09250
Pheniprazine may increase the hypotensive activities of Indoramin.
DB09251
Phenoxypropazine may increase the hypotensive activities of Indoramin.
DB09252
Pivhydrazine may increase the hypotensive activities of Indoramin.
DB09253
Safrazine may increase the hypotensive activities of Indoramin.
DB09254
Caroxazone may increase the hypotensive activities of Indoramin.
DB13875
Harmaline may increase the hypotensive activities of Indoramin.
DB13876
Brofaromine may increase the hypotensive activities of Indoramin.
DB00241
Butalbital may increase the hypotensive activities of Indoramin.
DB00312
Pentobarbital may increase the hypotensive activities of Indoramin.
DB00418
Secobarbital may increase the hypotensive activities of Indoramin.
DB00474
Methohexital may increase the hypotensive activities of Indoramin.
DB00599
Thiopental may increase the hypotensive activities of Indoramin.
DB00794
Primidone may increase the hypotensive activities of Indoramin.
DB00849
Methylphenobarbital may increase the hypotensive activities of Indoramin.
DB01154
Thiamylal may increase the hypotensive activities of Indoramin.
DB01174
Phenobarbital may increase the hypotensive activities of Indoramin.
DB01351
Amobarbital may increase the hypotensive activities of Indoramin.
DB01355
Hexobarbital may increase the hypotensive activities of Indoramin.
DB01483
Barbital may increase the hypotensive activities of Indoramin.
DB09001
Barbexaclone may increase the hypotensive activities of Indoramin.
DB00237
Butabarbital may increase the hypotensive activities of Indoramin.
DB00203
The risk or severity of hypotension, dyspepsia, and headache can be increased when Sildenafil is combined with Indoramin.
DB00235
The risk or severity of hypotension, dyspepsia, and headache can be increased when Milrinone is combined with Indoramin.
DB00820
The risk or severity of hypotension, dyspepsia, and headache can be increased when Tadalafil is combined with Indoramin.
DB00862
The risk or severity of hypotension, dyspepsia, and headache can be increased when Vardenafil is combined with Indoramin.
DB00975
The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Indoramin.
DB05266
The risk or severity of hypotension, dyspepsia, and headache can be increased when Ibudilast is combined with Indoramin.
DB06237
The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Indoramin.
DB06267
The risk or severity of hypotension, dyspepsia, and headache can be increased when Udenafil is combined with Indoramin.
DB11792
The risk or severity of hypotension, dyspepsia, and headache can be increased when Mirodenafil is combined with Indoramin.
DB12010
The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Indoramin.
DB00270
The risk or severity of hypotension can be increased when Indoramin is combined with Isradipine.
DB00343
The risk or severity of hypotension can be increased when Indoramin is combined with Diltiazem.
DB00347
The risk or severity of hypotension can be increased when Indoramin is combined with Trimethadione.
DB00381
The risk or severity of hypotension can be increased when Indoramin is combined with Amlodipine.
DB00393
The risk or severity of hypotension can be increased when Indoramin is combined with Nimodipine.
DB00401
The risk or severity of hypotension can be increased when Indoramin is combined with Nisoldipine.
DB00528
The risk or severity of hypotension can be increased when Indoramin is combined with Lercanidipine.
DB00555
The risk or severity of hypotension can be increased when Indoramin is combined with Lamotrigine.
DB00568
The risk or severity of hypotension can be increased when Indoramin is combined with Cinnarizine.
DB00593
The risk or severity of hypotension can be increased when Indoramin is combined with Ethosuximide.
DB00653
The risk or severity of hypotension can be increased when Indoramin is combined with Magnesium sulfate.
DB00836
The risk or severity of hypotension can be increased when Indoramin is combined with Loperamide.
DB00909
The risk or severity of hypotension can be increased when Indoramin is combined with Zonisamide.
DB01023
The risk or severity of hypotension can be increased when Indoramin is combined with Felodipine.
DB01054
The risk or severity of hypotension can be increased when Indoramin is combined with Nitrendipine.
DB01074
The risk or severity of hypotension can be increased when Indoramin is combined with Perhexiline.
DB01115
The risk or severity of hypotension can be increased when Indoramin is combined with Nifedipine.
DB01118
The risk or severity of hypotension can be increased when Indoramin is combined with Amiodarone.
DB01244
The risk or severity of hypotension can be increased when Indoramin is combined with Bepridil.
DB01388
The risk or severity of hypotension can be increased when Indoramin is combined with Mibefradil.
DB04825
The risk or severity of hypotension can be increased when Indoramin is combined with Prenylamine.
DB04838
The risk or severity of hypotension can be increased when Indoramin is combined with Cyclandelate.
DB04841
The risk or severity of hypotension can be increased when Indoramin is combined with Flunarizine.
DB04842
The risk or severity of hypotension can be increased when Indoramin is combined with Fluspirilene.
DB04920
The risk or severity of hypotension can be increased when Indoramin is combined with Clevidipine.
DB05246
The risk or severity of hypotension can be increased when Indoramin is combined with Methsuximide.
DB05885
The risk or severity of hypotension can be increased when Indoramin is combined with Seletracetam.
DB06152
The risk or severity of hypotension can be increased when Indoramin is combined with Nylidrin.
DB06283
The risk or severity of hypotension can be increased when Indoramin is combined with Ziconotide.
DB06446
The risk or severity of hypotension can be increased when Indoramin is combined with Dotarizine.
DB06712
The risk or severity of hypotension can be increased when Indoramin is combined with Nilvadipine.
DB07615
The risk or severity of hypotension can be increased when Indoramin is combined with Tranilast.
DB08162
The risk or severity of hypotension can be increased when Indoramin is combined with Fasudil.
DB08838
The risk or severity of hypotension can be increased when Indoramin is combined with Agmatine.
DB08980
The risk or severity of hypotension can be increased when Indoramin is combined with Fendiline.
DB08992
The risk or severity of hypotension can be increased when Indoramin is combined with Eperisone.
DB09089
The risk or severity of hypotension can be increased when Indoramin is combined with Trimebutine.
DB09090
The risk or severity of hypotension can be increased when Indoramin is combined with Pinaverium.
DB09229
The risk or severity of hypotension can be increased when Indoramin is combined with Aranidipine.
DB09230
The risk or severity of hypotension can be increased when Indoramin is combined with Azelnidipine.
DB09231
The risk or severity of hypotension can be increased when Indoramin is combined with Benidipine.
DB09232
The risk or severity of hypotension can be increased when Indoramin is combined with Cilnidipine.
DB09234
The risk or severity of hypotension can be increased when Indoramin is combined with Darodipine.
DB09235
The risk or severity of hypotension can be increased when Indoramin is combined with Efonidipine.
DB09238
The risk or severity of hypotension can be increased when Indoramin is combined with Manidipine.
DB09240
The risk or severity of hypotension can be increased when Indoramin is combined with Niludipine.
DB11960
The risk or severity of hypotension can be increased when Indoramin is combined with Carboxyamidotriazole.
DB12092
The risk or severity of hypotension can be increased when Indoramin is combined with Naftopidil.
DB12093
The risk or severity of hypotension can be increased when Indoramin is combined with Tetrahydropalmatine.
DB12131
The risk or severity of hypotension can be increased when Indoramin is combined with Vinpocetine.
DB12923
The risk or severity of hypotension can be increased when Indoramin is combined with Gallopamil.
DB13488
The risk or severity of hypotension can be increased when Indoramin is combined with Bencyclane.
DB13500
The risk or severity of hypotension can be increased when Indoramin is combined with Otilonium.
DB13725
The risk or severity of hypotension can be increased when Indoramin is combined with Terodiline.
DB13766
The risk or severity of hypotension can be increased when Indoramin is combined with Lidoflazine.
DB13791
The risk or severity of hypotension can be increased when Indoramin is combined with Penfluridol.
DB13835
The risk or severity of hypotension can be increased when Indoramin is combined with Caroverine.
DB13950
The risk or severity of hypotension can be increased when Indoramin is combined with WIN 55212-2.
DB13961
The risk or severity of hypotension can be increased when Indoramin is combined with Fish oil.
DB14063
The risk or severity of hypotension can be increased when Indoramin is combined with Dexverapamil.
DB14064
The risk or severity of hypotension can be increased when Indoramin is combined with Emopamil.
DB14065
The risk or severity of hypotension can be increased when Indoramin is combined with Lomerizine.
DB14066
The risk or severity of hypotension can be increased when Indoramin is combined with Tetrandrine.
DB14068
The risk or severity of hypotension can be increased when Indoramin is combined with Dexniguldipine.
DB00041
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indoramin.
DB00086
The risk or severity of adverse effects can be increased when Streptokinase is combined with Indoramin.
DB00268
The risk or severity of adverse effects can be increased when Ropinirole is combined with Indoramin.
DB00295
The risk or severity of adverse effects can be increased when Morphine is combined with Indoramin.
DB00296
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Indoramin.
DB00297
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Indoramin.
DB00323
The risk or severity of adverse effects can be increased when Tolcapone is combined with Indoramin.
DB00384
The risk or severity of adverse effects can be increased when Triamterene is combined with Indoramin.
DB00413
The risk or severity of adverse effects can be increased when Pramipexole is combined with Indoramin.
DB00421
The risk or severity of adverse effects can be increased when Spironolactone is combined with Indoramin.
DB00435
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Indoramin.
DB00486
The risk or severity of adverse effects can be increased when Nabilone is combined with Indoramin.
DB00594
The risk or severity of adverse effects can be increased when Amiloride is combined with Indoramin.
DB00631
The risk or severity of adverse effects can be increased when Clofarabine is combined with Indoramin.
DB00681
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.
DB00703
The risk or severity of adverse effects can be increased when Methazolamide is combined with Indoramin.
DB00714
The risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin.
DB00742
The risk or severity of adverse effects can be increased when Mannitol is combined with Indoramin.
DB00755
The risk or severity of adverse effects can be increased when Tretinoin is combined with Indoramin.
DB00872
The risk or severity of adverse effects can be increased when Conivaptan is combined with Indoramin.
DB00883
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Indoramin.
DB00887
The risk or severity of adverse effects can be increased when Bumetanide is combined with Indoramin.
DB00903
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Indoramin.
DB00922
The risk or severity of adverse effects can be increased when Levosimendan is combined with Indoramin.
DB01002
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Indoramin.
DB01020
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Indoramin.
DB01041
The risk or severity of adverse effects can be increased when Thalidomide is combined with Indoramin.
DB01113
The risk or severity of adverse effects can be increased when Papaverine is combined with Indoramin.
DB01144
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Indoramin.
DB01169
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.
DB01229
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Indoramin.
DB01282
The risk or severity of adverse effects can be increased when Carbetocin is combined with Indoramin.
DB01612
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Indoramin.
DB04899
The risk or severity of adverse effects can be increased when Nesiritide is combined with Indoramin.
DB06292
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Indoramin.
DB08822
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indoramin.
DB08907
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Indoramin.
DB09038
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Indoramin.
DB09077
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Indoramin.
DB09112
The risk or severity of adverse effects can be increased when Nitrous acid is combined with Indoramin.
DB09279
The risk or severity of adverse effects can be increased when Fimasartan is combined with Indoramin.
DB09286
The risk or severity of adverse effects can be increased when Pipamperone is combined with Indoramin.
DB09292
The risk or severity of adverse effects can be increased when Sacubitril is combined with Indoramin.
DB00211
The therapeutic efficacy of Midodrine can be decreased when used in combination with Indoramin.
DB00368
The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Indoramin.
DB00388
The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Indoramin.
DB00610
The therapeutic efficacy of Metaraminol can be decreased when used in combination with Indoramin.
DB00668
The therapeutic efficacy of Epinephrine can be decreased when used in combination with Indoramin.
DB00723
The therapeutic efficacy of Methoxamine can be decreased when used in combination with Indoramin.
DB00841
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Indoramin.
DB00935
The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indoramin.
DB01186
The therapeutic efficacy of Pergolide can be decreased when used in combination with Indoramin.
DB01253
The therapeutic efficacy of Ergometrine can be decreased when used in combination with Indoramin.
DB01472
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Indoramin.
DB01579
The therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Indoramin.
DB06262
The therapeutic efficacy of Droxidopa can be decreased when used in combination with Indoramin.
DB06706
The therapeutic efficacy of Isometheptene can be decreased when used in combination with Indoramin.
DB06764
The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Indoramin.
DB09202
The therapeutic efficacy of Cirazoline can be decreased when used in combination with Indoramin.
DB11124
The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Indoramin.
DB00320
Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00321
Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00334
Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00363
Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00420
Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00450
Droperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00458
Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00477
Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00540
Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00543
Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00590
Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00598
Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00622
Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00656
Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00661
Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00679
Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00692
Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00696
Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00699
Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00706
Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00726
Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00777
Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00797
Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00831
Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00875
Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00908
Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00925
Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01136
Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01142
Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01149
Nefazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01162
Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01200
Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01267
Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01295
Bevantolol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01403
Methotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01608
Periciazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01614
Acepromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01622
Thioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB01624
Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB04855
Dronedarone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB04946
Iloperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB06153
Pizotifen may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB06207
Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB06216
Asenapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB09128
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.
DB09206
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimazosin.
DB09239
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.
DB12230
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bunazosin.
DB12278
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.
DB12661
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.
DB12752
Indoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bucindolol.
DB01238
Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB14185
Aripiprazole lauroxil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.
DB00159
The therapeutic efficacy of Indoramin can be decreased when used in combination with Icosapent.
DB00244
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mesalazine.
DB00328
The therapeutic efficacy of Indoramin can be decreased when used in combination with Indomethacin.
DB00461
The therapeutic efficacy of Indoramin can be decreased when used in combination with Nabumetone.
DB00465
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ketorolac.
DB00469
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tenoxicam.
DB00482
The therapeutic efficacy of Indoramin can be decreased when used in combination with Celecoxib.
DB00500
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tolmetin.
DB00533
The therapeutic efficacy of Indoramin can be decreased when used in combination with Rofecoxib.
DB00554
The therapeutic efficacy of Indoramin can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Indoramin can be decreased when used in combination with Fenoprofen.
DB00580
The therapeutic efficacy of Indoramin can be decreased when used in combination with Valdecoxib.
DB00586
The therapeutic efficacy of Indoramin can be decreased when used in combination with Diclofenac.
DB00605
The therapeutic efficacy of Indoramin can be decreased when used in combination with Sulindac.
DB00712
The therapeutic efficacy of Indoramin can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Indoramin can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mefenamic acid.
DB00788
The therapeutic efficacy of Indoramin can be decreased when used in combination with Naproxen.
DB00795
The therapeutic efficacy of Indoramin can be decreased when used in combination with Sulfasalazine.
DB00812
The therapeutic efficacy of Indoramin can be decreased when used in combination with Phenylbutazone.
DB00814
The therapeutic efficacy of Indoramin can be decreased when used in combination with Meloxicam.
DB00821
The therapeutic efficacy of Indoramin can be decreased when used in combination with Carprofen.
DB00861
The therapeutic efficacy of Indoramin can be decreased when used in combination with Diflunisal.
DB00936
The therapeutic efficacy of Indoramin can be decreased when used in combination with Salicylic acid.
DB00939
The therapeutic efficacy of Indoramin can be decreased when used in combination with Meclofenamic acid.
DB00991
The therapeutic efficacy of Indoramin can be decreased when used in combination with Oxaprozin.
DB01009
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ketoprofen.
DB01014
The therapeutic efficacy of Indoramin can be decreased when used in combination with Balsalazide.
DB01050
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ibuprofen.
DB01250
The therapeutic efficacy of Indoramin can be decreased when used in combination with Olsalazine.
DB01283
The therapeutic efficacy of Indoramin can be decreased when used in combination with Lumiracoxib.
DB01397
The therapeutic efficacy of Indoramin can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Indoramin can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Indoramin can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Indoramin can be decreased when used in combination with Antrafenine.
DB01424
The therapeutic efficacy of Indoramin can be decreased when used in combination with Aminophenazone.
DB01435
The therapeutic efficacy of Indoramin can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tiaprofenic acid.
DB01628
The therapeutic efficacy of Indoramin can be decreased when used in combination with Etoricoxib.
DB02224
The therapeutic efficacy of Indoramin can be decreased when used in combination with Taxifolin.
DB03585
The therapeutic efficacy of Indoramin can be decreased when used in combination with Oxyphenbutazone.
DB04725
The therapeutic efficacy of Indoramin can be decreased when used in combination with Licofelone.
DB04743
The therapeutic efficacy of Indoramin can be decreased when used in combination with Nimesulide.
DB04812
The therapeutic efficacy of Indoramin can be decreased when used in combination with Benoxaprofen.
DB04817
The therapeutic efficacy of Indoramin can be decreased when used in combination with Metamizole.
DB04828
The therapeutic efficacy of Indoramin can be decreased when used in combination with Zomepirac.
DB05095
The therapeutic efficacy of Indoramin can be decreased when used in combination with Cimicoxib.
DB06725
The therapeutic efficacy of Indoramin can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Indoramin can be decreased when used in combination with Aceclofenac.
DB06737
The therapeutic efficacy of Indoramin can be decreased when used in combination with Zaltoprofen.
DB07402
The therapeutic efficacy of Indoramin can be decreased when used in combination with Azapropazone.
DB08439
The therapeutic efficacy of Indoramin can be decreased when used in combination with Parecoxib.
DB08797
The therapeutic efficacy of Indoramin can be decreased when used in combination with Salicylamide.
DB08940
The therapeutic efficacy of Indoramin can be decreased when used in combination with Kebuzone.
DB08942
The therapeutic efficacy of Indoramin can be decreased when used in combination with Isoxicam.
DB08951
The therapeutic efficacy of Indoramin can be decreased when used in combination with Indoprofen.
DB08955
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ibuproxam.
DB08976
The therapeutic efficacy of Indoramin can be decreased when used in combination with Floctafenine.
DB08981
The therapeutic efficacy of Indoramin can be decreased when used in combination with Fenbufen.
DB08984
The therapeutic efficacy of Indoramin can be decreased when used in combination with Etofenamate.
DB08991
The therapeutic efficacy of Indoramin can be decreased when used in combination with Epirizole.
DB09084
The therapeutic efficacy of Indoramin can be decreased when used in combination with Benzydamine.
DB09213
The therapeutic efficacy of Indoramin can be decreased when used in combination with Dexibuprofen.
DB09214
The therapeutic efficacy of Indoramin can be decreased when used in combination with Dexketoprofen.
DB09215
The therapeutic efficacy of Indoramin can be decreased when used in combination with Droxicam.
DB09216
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tolfenamic acid.
DB09217
The therapeutic efficacy of Indoramin can be decreased when used in combination with Firocoxib.
DB09218
The therapeutic efficacy of Indoramin can be decreased when used in combination with Clonixin.
DB09285
The therapeutic efficacy of Indoramin can be decreased when used in combination with Morniflumate.
DB09288
The therapeutic efficacy of Indoramin can be decreased when used in combination with Propacetamol.
DB09295
The therapeutic efficacy of Indoramin can be decreased when used in combination with Talniflumate.
DB11455
The therapeutic efficacy of Indoramin can be decreased when used in combination with Robenacoxib.
DB11466
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tepoxalin.
DB11518
The therapeutic efficacy of Indoramin can be decreased when used in combination with Flunixin.
DB12399
The therapeutic efficacy of Indoramin can be decreased when used in combination with Polmacoxib.
DB12445
The therapeutic efficacy of Indoramin can be decreased when used in combination with Nitroaspirin.
DB12545
The therapeutic efficacy of Indoramin can be decreased when used in combination with Indobufen.
DB12610
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ebselen.
DB13001
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tinoridine.
DB13167
The therapeutic efficacy of Indoramin can be decreased when used in combination with Alclofenac.
DB13217
The therapeutic efficacy of Indoramin can be decreased when used in combination with Fentiazac.
DB13232
The therapeutic efficacy of Indoramin can be decreased when used in combination with Suxibuzone.
DB13286
The therapeutic efficacy of Indoramin can be decreased when used in combination with Bumadizone.
DB13314
The therapeutic efficacy of Indoramin can be decreased when used in combination with Alminoprofen.
DB13371
The therapeutic efficacy of Indoramin can be decreased when used in combination with Difenpiramide.
DB13407
The therapeutic efficacy of Indoramin can be decreased when used in combination with Nifenazone.
DB13432
The therapeutic efficacy of Indoramin can be decreased when used in combination with Lonazolac.
DB13481
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tenidap.
DB13524
The therapeutic efficacy of Indoramin can be decreased when used in combination with Propyphenazone.
DB13527
The therapeutic efficacy of Indoramin can be decreased when used in combination with Proglumetacin.
DB13538
The therapeutic efficacy of Indoramin can be decreased when used in combination with Guacetisal.
DB13544
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ethenzamide.
DB13612
The therapeutic efficacy of Indoramin can be decreased when used in combination with Carbaspirin calcium.
DB13629
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mofebutazone.
DB13649
The therapeutic efficacy of Indoramin can be decreased when used in combination with Proquazone.
DB13657
The therapeutic efficacy of Indoramin can be decreased when used in combination with Benorilate.
DB13722
The therapeutic efficacy of Indoramin can be decreased when used in combination with Pirprofen.
DB13783
The therapeutic efficacy of Indoramin can be decreased when used in combination with Acemetacin.
DB13860
The therapeutic efficacy of Indoramin can be decreased when used in combination with Imidazole salicylate.
DB14059
The therapeutic efficacy of Indoramin can be decreased when used in combination with SC-236.
DB14060
The therapeutic efficacy of Indoramin can be decreased when used in combination with NS-398.
DB14938
The therapeutic efficacy of Indoramin can be decreased when used in combination with Flurbiprofen axetil.
DB09212
The therapeutic efficacy of Indoramin can be decreased when used in combination with Loxoprofen.
DB09236
Indoramin may increase the hypotensive activities of Lacidipine.
DB00898
Ethanol may increase the hypotensive activities of Indoramin.
DB09227
Indoramin may increase the antihypertensive activities of Barnidipine.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Indoramin.
DB06707
Indoramin may decrease the hypertensive activities of Levonordefrin.
DB12927
Indoramin may decrease the hypertensive activities of Theodrenaline.
DB13917
Indoramin may decrease the hypertensive activities of Deoxyepinephrine.
DB00182
The therapeutic efficacy of Indoramin can be decreased when used in combination with Amphetamine.
DB00191
The therapeutic efficacy of Indoramin can be decreased when used in combination with Phentermine.
DB00852
The therapeutic efficacy of Indoramin can be decreased when used in combination with Pseudoephedrine.
DB00865
The therapeutic efficacy of Indoramin can be decreased when used in combination with Benzphetamine.
DB00937
The therapeutic efficacy of Indoramin can be decreased when used in combination with Diethylpropion.
DB01255
The therapeutic efficacy of Indoramin can be decreased when used in combination with Lisdexamfetamine.
DB01365
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mephentermine.
DB01442
The therapeutic efficacy of Indoramin can be decreased when used in combination with MMDA.
DB01454
The therapeutic efficacy of Indoramin can be decreased when used in combination with Midomafetamine.
DB01467
The therapeutic efficacy of Indoramin can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
DB01484
The therapeutic efficacy of Indoramin can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The therapeutic efficacy of Indoramin can be decreased when used in combination with Tenamfetamine.
DB01556
The therapeutic efficacy of Indoramin can be decreased when used in combination with Chlorphentermine.
DB01566
The therapeutic efficacy of Indoramin can be decreased when used in combination with Methylenedioxyethamphetamine.
DB01576
The therapeutic efficacy of Indoramin can be decreased when used in combination with Dextroamphetamine.
DB01577
The therapeutic efficacy of Indoramin can be decreased when used in combination with Metamfetamine.
DB09480
The therapeutic efficacy of Indoramin can be decreased when used in combination with Iofetamine I-123.
DB12080
The therapeutic efficacy of Indoramin can be decreased when used in combination with Ritobegron.
DB13108
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mephedrone.
DB13624
The therapeutic efficacy of Indoramin can be decreased when used in combination with Methoxyphenamine.
DB13703
The therapeutic efficacy of Indoramin can be decreased when used in combination with Gepefrine.
DB13940
The therapeutic efficacy of Indoramin can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB00190
The risk or severity of hypotension can be increased when Carbidopa is combined with Indoramin.
DB11823
The risk or severity of hypertension can be increased when Esketamine is combined with Indoramin.
DB14754
The risk or severity of hypertension can be increased when Solriamfetol is combined with Indoramin.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Indoramin.
DB13946
Testosterone undecanoate may increase the hypertensive activities of Indoramin.
DB00575
The risk or severity of hypotension can be increased when Clonidine is combined with Indoramin.
DB01224
Quetiapine may increase the hypotensive activities of Indoramin.
DB00246
Ziprasidone may increase the antihypertensive activities of Indoramin.
DB00232
The therapeutic efficacy of Indoramin can be increased when used in combination with Methyclothiazide.
DB00436
The therapeutic efficacy of Indoramin can be increased when used in combination with Bendroflumethiazide.
DB00774
The therapeutic efficacy of Indoramin can be increased when used in combination with Hydroflumethiazide.
DB00880
The therapeutic efficacy of Indoramin can be increased when used in combination with Chlorothiazide.
DB00999
The therapeutic efficacy of Indoramin can be increased when used in combination with Hydrochlorothiazide.
DB00606
The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Indoramin.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Indoramin.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Indoramin.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Indoramin.
DB00562
The therapeutic efficacy of Indoramin can be increased when used in combination with Benzthiazide.
DB13430
The therapeutic efficacy of Indoramin can be increased when used in combination with Mebutizide.
DB00808
The therapeutic efficacy of Indoramin can be increased when used in combination with Indapamide.

序列

实验性质

Melting Point
208-210
U.S. Patent 3,527,761

外部标识符

resource：ChEBI
identifier：135470
resource：PubChem Compound
identifier：33625
resource：PubChem Substance
identifier：310264915
resource：KEGG Drug
identifier：D04531
resource：ChemSpider
identifier：31014
resource：BindingDB
identifier：50033113
resource：Wikipedia
identifier：Indoramin
resource：ChEMBL
identifier：CHEMBL279516
resource：ZINC
identifier：ZINC000000001567
resource：RxCUI
identifier：5784

外部链接

Drugs.com
http://www.drugs.com/international/indoramin.html

路径

目标

id:BE0000501
name:Alpha-1A adrenergic receptor
organism:Humans
action:antagonist
Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201-7.
Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
known-action:unknown
name:Alpha-1A adrenergic receptor
general-function:Protein heterodimerization activity
specific-function:This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
gene-name:ADRA1A
locus:8p21-p11.2
cellular-location:Nucleus membrane
transmembrane-regions:28-51 65-88 100-122 144-167 182-205 274-297 306-329
signal-regions:
theoretical-pi:9.23
molecular-weight:51486.005
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:277GenAtlasADRA1AGenBank Gene DatabaseD25235GenBank Protein Database433201IUPHAR22Guide to Pharmacology22UniProtKBP35348UniProt AccessionADA1A_HUMAN
synonyms:ADRA1CAlpha-1A adrenoceptorAlpha-1A adrenoreceptorAlpha-1C adrenergic receptorAlpha-adrenergic receptor 1c
amino-acid-sequence:>lcl|BSEQ0001000|Alpha-1A adrenergic receptor MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV
gene-sequence:>lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A) ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT GAGAACGGGGAGGAAGTCTAG
pfams:PF000017tm_1
go-classifiers:componentcytosolcomponentintegral component of plasma membranecomponentnuclear membranecomponentnucleuscomponentplasma membranefunctionalpha1-adrenergic receptor activityfunctionprotein heterodimerization activityprocessactivation of phospholipase C activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessagingprocessapoptotic processprocesscalcium ion transport into cytosolprocesscell-cell signalingprocessG-protein coupled receptor signaling pathwayprocessintracellular signal transductionprocessnegative regulation of cell proliferationprocessnegative regulation of Rho protein signal transductionprocessnorepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocesspositive regulation of action potentialprocesspositive regulation of cardiac muscle contractionprocesspositive regulation of cytosolic calcium ion concentrationprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of MAPK cascadeprocesspositive regulation of protein kinase C signalingprocesspositive regulation of smooth muscle contractionprocesspositive regulation of synaptic transmission, GABAergicprocesspositive regulation of vasoconstrictionprocessresponse to drugprocessresponse to hormoneprocesssignal transductionprocesssmooth muscle contraction

酶

载体

运输工具

药物反应

效应

不良反应